Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIERCe
NCT07227571Phase 1Recruiting
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Jan 2026
- Primary completion
- Jan 2029
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of FH-FOLR1 CAR T cells in osteosarcoma (OS), sponsored by Fred Hutchinson Cancer Center. Primary endpoints: Incidence of treatment-related unexpected grade 3 or higher toxicity at 28 days and Maximum tolerated dose/recommended phase 2 dose at 28 days. Started Jan 2026; status: recruiting.
02
Drugs
FH-FOLR1 CAR T cells
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on NCT07227571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07227571.